• APARNA C Department of Pharmaceutics, Sri Venkateshwara College of Pharmacy, Hyderabad, Telangana, India.
  • ANUSHA M Department of Pharmaceutics, Sri Venkateshwara College of Pharmacy, Hyderabad, Telangana, India.
  • MANISHA B Department of Pharmaceutics, Sri Venkateshwara College of Pharmacy, Hyderabad, Telangana, India. https://orcid.org/0000-0002-1258-1450




Candesartan cilexetil, shake flask method, liquid lipids


Objective: The main aim of our investigation was to enhance the dissolution of Candesartan Cilexetil (CC), a prodrug of Candesartan, used in the treatment of hypertension. CC bioavailability is dissolution rate limited. The drug was formulated using various excipients such as surfactants, and liquid lipids to improve solubility, dissolution, and hence bioavailability.

Methods: The solubility of CC was determined at 25°C by shake flask method and those showing maximum solubility were selected for the formulation of CC. In vitro dissolution studies were done in different media in pH 6.8 phosphate buffer with 1% SLS, tween 20, and 0.1 N HCl with 1% SLS. The surface morphology of LBDDS was studied with scanning electron microscope (SEM) and the crystallinity of the drug and the formulation were studied using X-ray diffraction (XRD).

Results: CC showed maximum solubility in transcutol and labrasol, which, hence, were selected as excipients for the formulation of CC capsules. Drug release was high in 0.1 N HCl with 1% SLS and, hence, was selected as the dissolution medium. The dissolution profile for formulation F5 containing the drug with transcutol and labrasol showed the highest drug release among all formulations, that is, 94.09%. The SEM of the F5 formulation showed that the drug was completely embedded into the lipid matrix and particles were spherical and porous with a size of around 25 μ. XRD of formulation F5 indicated the absence of crystallinity in CC capsules containing transcutol and labrasol.

Conclusion: It was concluded that CC containing transcutol and labrasol significantly increases the solubility and dissolution of the drug.


Download data is not yet available.


Figueroa-Campos A, Sánchez-Dengra B, Merino V, Dahan A, González-Álvarez I, García-Arieta A, et al. Candesartan cilexetil in-vitro in-vivo correlation: Predictive dissolution as a development tool. Pharmaceutics 2020;12:633. doi: 10.3390/pharmaceutics12070633, PMID 32640620

Sravya RD, Deveswaran R, Bharath S, Basavaraj BV, Madhavan V. Bharath S. Development of oro-dispersible tablets of candesartan cilexetil-β-cyclodextrin complex. J Pharm (Cairo) 2013;2013:583536.

Mahajan A, Kaur S, Kaur S. Design, formulation, and characterization of stearic acid-based solid lipid nanoparticles of candesartan cilexetil to augment its oral bioavailability. Asian J Pharm Clin Res 2018;11:344-50. doi: 10.22159/ajpcr.2018.v11i4.23849

Reddy BV, Navanetha K. Formulation and evaluation of orodispersible tablets of candesartan. Pharm Innov J 2015;4:25-32.

Priya HS, Pattil BS, Jeevangi RS. Formulation and development of candesartan cilexetil fast dissolving tablets by the sublimation technique. Am J Pharm Tech Res 2019;9:2249-3387.

Fotouch KA, Allam A, El-Sayed AM, El-Badry M. Development and in-vitro/in-vivo performance of the self nanoemulsifying drug delivery systems loaded with candesartan cilexetil. Eur J Pharm Sci 2017;109:503-13.

Anwar W, Davaba HM, Afouna M, Ahmed AM. Screening study for the formulation variables and characterization of candesartan cilexetil loaded nano stuctured lipid carriers. Univ J Pharma Res 2019;4:8-9.

Thakkar H, Nangesh J, Parmar M, Divyakantpatel P. Formulation and characterization of lipid-based drug delivery system of raloxifen microemulsion and self-microemulsifying drug delivery system. J Pharm Bioallied Sci 2011;3:422-8.

Constantinides PP. Lipid micro emulsions for improving the drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res 1995;12:1561-72. doi: 10.1023/a:1016268311867, PMID 8592652

Devi AS, Peddinti AP. Formulation and evaluation of the solid dispersion tablets of the poorly water soluble drug candesartan cilexetil using polaxamer 407. Int J Pharm Sci Rev Res 2014;29:67-73.

Pouton CW, Porter CJ. Formulation of lipid-based drug delivery systems for oral administration. Adv Drug Deliv Rev 2008;60:625-37.

Liu L, Zhao MH, Xu H, Wang SN, Li LS. Loading of tacrolimus containing the lipid based drug delivery system into mesoporous silica for extended release. Asian J Pharm Sci 2016;10:751-9.

Surampalli G, Nanjwade BK, Patil PA, Chilla R. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-GP inhibition for optimal drug delivery: In vitro and in vivo evaluation. Drug Deliv 2016;23:2124-38. doi: 10.3109/10717544.2014.945017, PMID 25080228

Sayyad FJ, Tulsankar SL, Koplap UB. Design and development of the liquisolid compact of candesartan cilexetil to enhance dissolution. J Pharm Res 2013;7:381-8.

Prabhu S, Ortega M, Ma C. Novel lipid-based formulation enhancing the in-vitro dissolution and permeability characteristics of poorly water-soluble model drug, pircoxicam. Int J Pharm 2005;301:209-16. doi: 10.1016/j.ijpharm.2005.05.032, PMID 16046087

Nekkanti V, Kalepu S. Development of the novel lipid based drug delivery system for raloxifen hydrochloride. Int Res J Pharm 2012;3:166-73.

Kamalakkannan V, Puratchikody A, Ramanathan L. Development and the characterization of controlled release polar lipid micro particles of the candesartan cilexetil by solid dispersions. Res Pharm Sci 2013;8:125-36. PMID 24019822

Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticlesfor the oral delivery: Characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 2016;23:395-404.



How to Cite

C, A., A. M, and M. B. “ENHANCEMENT OF DISSOLUTION OF CANDESARTAN CILEXETIL”. Asian Journal of Pharmaceutical and Clinical Research, vol. 16, no. 3, Mar. 2023, pp. 148-51, doi:10.22159/ajpcr.2023.v16i3.46626.



Original Article(s)